Madison-based Exact Sciences will be acquired by Abbott Laboratory for roughly $23 billion in a deal that was announced Nov.

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and ...

The company will maintain its presence in Madison and CEO Kevin Conroy will remain “in an advisory role,” said Zach Brandon, ...

Exact Sciences markets Cologuard as a non-invasive, convenient test. The traditional method of testing for colorectal cancer ...

Founded near Boston in 1995, the company grew to become a biotech giant largely on the strength of its Cologuard cancer ...

Abbott agrees to acquire Exact Sciences for an estimated value up to $23 billion. The acquisition will include Exact Sciences' cancer ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts ...

Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its ...

Abbott will acquire Madison-based cancer diagnostics company Exact Sciences in a $21 billion deal, expanding its global diagnostics portfolio.

When companies do solve that puzzle, the rewards can be huge: As Modern CEO went to press, Exact Sciences announced it was selling to Abbott in a deal valued at $21 billion.

Global healthcare leader Abbott announced Thursday that it has reached a $23 billion deal to acquire Exact Sciences.